Managing AEs Associated With The EV-302 Trial Regimen in Bladder Cancer
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Top 5 Takeaways for Genitourinary Cancer Care From 2025 ASCO GU
Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.
Multidisciplinary Approach for AE Management After Pembrolizumab/ICI
“We’ve seen with the initial anti-CTLA-4 ipilimumab experience that, as time went by, we were better at identifying and managing toxicities,” stated Omid Hamad, MD.
Addressing Social Norms Influencing Receipt of Aggressive End-of-Life Care
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Tambiciclib/Zanubrutinib Yields Promising Responses in R/R DLBCL
Tambiciclib plus zanubrutinib doubled the expected ORR of zanubrutinib monotherapy, eliciting an ORR of 67% in patients with relapsed or refractory DLBCL.
Leading Early Conversations About ICD Use in End-of-Life Cancer Care
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
The Potential for Improved Processes, Outcomes, and Economics of Health Care
DOGE hopes to solve rampant inefficiencies in US healthcare that contribute to unsustainable costs and a broken system by cutting spending and administrative waste.
Identifying Regional Kidney Cancer Needs Via International Collaboration
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Improving End-of-Life Care in ICD Users With Advanced Cancers
Understanding patient preferences for intensive end-of-life treatment may better inform research assessing patients with terminal cancer diagnoses.
The Intricacies of Discontinuation Rates With Pembrolizumab Across Cancer Types
A pooled analysis found pembrolizumab has a discontinuation rate of 12.7%, and a major key to handling it is maintaining good communication between the doctor and the patient.
Cu-67 SAR-bisPSMA Granted Fast Track Designation for Metastatic CRPC
Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.
Petosemtamab Combo Earns Breakthrough Therapy Status in PD-L1+ HNSCC
Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.
3 Things You Should Know About Adverse Events With Targeted Therapies for DLBCL
Tips from experts on how to think about and manage adverse events in patients with diffuse large B-cell lymphoma.
Protecting Sexual Function Via The Hood Technique in Prostate Cancer
“Even after doing 10,000 of these operations, we are tweaking [the hood technique]…to make things better,” according to Ash Tewari, MD, MBBS, MCh, FRCS.
Enfortumab Vedotin Combo Yields ‘Transformative’ Urothelial Cancer Outcomes
Updated findings from the phase 3 EV-302 trial show enduring responses and survival improvements with enfortumab vedotin plus pembrolizumab.
Neoadjuvant Nivolumab/Chemo Improves OS Vs Chemotherapy in Resectable NSCLC
Updated, comprehensive OS results with the combination in resectable NSCLC will be shared in a future peer-reviewed setting.
Zongertinib Receives FDA Priority Review in HER2–Mutant Advanced NSCLC
Efficacy results from cohort 1 of the phase 1b Beamion LUNG-1 trial support the decision to review zongertinib in HER2-mutant advanced NSCLC.
Outlining the Impact of AI on Multidisciplinary Oncology Practice
AI-powered tools may help alleviate doctor burnout and give clinicians more time to directly engage with patients.
3 Things You Should Know About Identifying and Treating Epithelioid Sarcoma
Experts discuss epithelioid sarcoma diagnosis, management, and targeted therapies, and highlight 3 things everyone should know about treatment.
Dordaviprone Earns Priority Review in H3 K27M-Mutant Diffuse Glioma
The FDA has accepted an NDA and set a PDUFA date of August 18, 2025, for the decision on dordaviprone in H3 K27M-mutant diffuse glioma.
Study Finds Recent Falls, Inability to Balance on Left Leg Indicate OS Decrease in NHL
Adverse physical functions were indicative of reduced survival and increased risk of ICANS in patients with non-Hodgkin lymphoma who were previously treated with CAR T-cell therapy.
Newer, Alternative Treatment Methods May Improve Brain Tumor Care
An individualized vaccine as well as aerosolized medicines are 2 novel forms of treatment that are under development for managing brain tumors.
Darolutamide/ADT Yields Consistent Outcomes Across HSPC Age Subgroups
Data show improvements in overall survival and time to subsequent therapy initiation with darolutamide plus ADT/docetaxel.
Advancing the MZL Landscape Through the MZL Workshop
Davide Rossi, MD, spoke about the impact of the MZL workshop and his hopes for the future of treatment and medicine in MZL.
Age Did Not Negatively Impact Response From CAR T-Cell Therapy in R/R LBCL
Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.
Belzutifan Receives European Approval in Localized/Advanced RCC Indications
LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.
Venetoclax/Ibrutinib Significantly Improves PFS in Mantle Cell Lymphoma
The safety profile of ibrutinib/venetoclax in the phase 3 SYMPATICO trial was consistent with the known profiles for each individual agent.
Forecast on Eliminating Cancer Disparities Looks to Ethnic Enclave Research
Scarlett Lin Gomez, MPH, PhD, highlights facts from her research that are impacting cancer disparities and how she is finding ways to improve them.
Ide-Cel Yields High Response Rates in Post-Transplant Myeloma Patients
Idecabtagene vicleucel led to high rates of MRD negativity in multiple myeloma who responded did not have complete responses to first-line therapy.
Promising Trials May Have an Impact in the Brain Tumor Environment
Frances Chow, MD, and Elizabeth Ren Zhang-Velten, MD, PhD, spoke about several facets of the current brain tumor landscape, including targeted therapies.
